Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 14/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6250374 | 0.83 | PTGS2 (0.44) | PTGS2POLBMAPTTDP1L3MBTL1 | |
| SCHEMBL6535146 | 0.83 | PTGS2 (0.44) | PTGS2POLBMAPTTDP1L3MBTL1 | |
| SCHEMBL6984241 | 0.83 | PTGS2 (0.44) | PTGS2POLBMAPTTDP1L3MBTL1 | |
| SCHEMBL6699050 | 0.81 | PTGS2 (0.48) | PTGS2MAPTTDP1L3MBTL1SMN1; SMN2 | |
| SCHEMBL9351941 | 0.80 | POLB (0.49) | PTGS2POLBMAPTTDP1L3MBTL1 | |
| SCHEMBL6251303 | 0.79 | PTGS2 (0.41) | PTGS2POLBMAPTTDP1L3MBTL1 | |
| SCHEMBL9351756 | 0.78 | POLB (0.47) | PTGS2POLBMAPTTDP1L3MBTL1 | |
| SCHEMBL6031819 | 0.78 | PTGS2 (0.62) | PTGS2TDP1TSHRKDM4EHPGD | |
| SCHEMBL9615762 | 0.77 | MAPT (0.55) | PTGS2POLBMAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL5835024 | 0.77 | TDP1 (0.55) | PTGS2TDP1L3MBTL1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0958275-A4 | SELECTIVE INHIBITORS OF PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-2 | UNIV VANDERBILT (US) | 2004-12-01 | — | — | EP | claimed |
| US-6284918-B1 | ENZYME INHIBITORS | VANDERBILT UNIVERSITY | 2001-09-04 | — | — | US | claimed |
| EP-0958275-A1 | SELECTIVE INHIBITORS OF PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-2 | VANDERBILT UNIVERSITY (US) | 1999-11-24 | — | — | EP | claimed |
| US-5973191-A | AN ACETOXYPHENYLALKYL SULFIDE, SALT OR HYDRATE | VANDERBILT UNIVERSITY (US) | 1999-10-26 | — | — | US | claimed |
| WO-1998029382-A1 | SELECTIVE INHIBITORS OF PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-2 | VANDERBILT UNIVERSITY (US) | 1998-07-09 | — | — | WO | claimed |
| EP-1194141-B1 | ANTIVIRAL THERAPY | UNIV MEDISCH CENTRUM UTRECHT (NL) | 2005-08-17 | — | — | EP | disclosed |
| US-20050059745-A1 | Antiviral therapy | MARIA NOTTET JOHANNES SERVATIU (NL) | 2005-03-17 | — | — | US | disclosed |
| EP-0958275-A4 | SELECTIVE INHIBITORS OF PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-2 | UNIV VANDERBILT (US) | 2004-12-01 | — | — | EP | disclosed |
| US-6787573-B2 | THERAPY FOR DRUG RESISTANT VIRUS | UNIVERSITEIT UTRECHT (NL) | 2004-09-07 | — | — | US | disclosed |
| EP-1452605-A1 | Method for determining antiviral activity | Universiteit Utrecht Holding B.V. (NL) | 2004-09-01 | — | — | EP | disclosed |
| EP-1263429-B1 | ANTIVIRAL THERAPY | UNIV UTRECHT (NL) | 2004-07-14 | — | — | EP | disclosed |
| US-20030171441-A1 | Therapy for drug resistant virus | UNIVERSITEIT UTRECHT (NL) | 2003-09-11 | — | — | US | disclosed |
| EP-1194141-A1 | ANTIVIRAL THERAPY | Universitair Medisch Centrum Utrecht (NL) | 2002-04-10 | — | — | EP | disclosed |
| WO-2001068086-A1 | ANTIVIRAL THERAPY | UNIVERSITEIT UTRECHT (NL) | 2001-09-20 | — | — | WO | disclosed |
| US-6284918-B1 | ENZYME INHIBITORS | VANDERBILT UNIVERSITY | 2001-09-04 | — | — | US | disclosed |
| WO-2001001985-A1 | ANTIVIRAL THERAPY | UNIVERSITAIR MEDISCH CENTRUM UTRECHT (NL) | 2001-01-11 | — | — | WO | disclosed |
| EP-1064940-A1 | Antiviral therapy | Universitair Medisch Centrum Utrecht (NL) | 2001-01-03 | — | — | EP | disclosed |
| EP-0958275-A1 | SELECTIVE INHIBITORS OF PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-2 | VANDERBILT UNIVERSITY (US) | 1999-11-24 | — | — | EP | disclosed |
| US-5973191-A | AN ACETOXYPHENYLALKYL SULFIDE, SALT OR HYDRATE | VANDERBILT UNIVERSITY (US) | 1999-10-26 | — | — | US | disclosed |
| WO-1998029382-A1 | SELECTIVE INHIBITORS OF PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-2 | VANDERBILT UNIVERSITY (US) | 1998-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059745-A1 | Antiviral therapy | ZC3HAV1, EIF2AK2, MAVS | PTGS2 4159/4885POLB 231/4885MAPT 1701/4885 |
| US-20030171441-A1 | Therapy for drug resistant virus | ZC3HAV1, NHERF1, ABCC1 | PTGS2 4388/4885POLB 1335/4885MAPT 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.